Further, the company also intends to begin marketing its current portfolio biomarkers to research laboratories globally.
Michael Cohen, president and CEO of National Stem Cell Holding, said: “Our new name reflects the fact that we are emerging out of our R&D stage and commencing the commercialization of our technologies. These technologies relate in great part to the identification of proteins, and their structure and functions within the emerging biotherapeutics field.”